Larotrectinib

Larotrectinib Brand Name– VITRAKVI

What is Larotrectinib

Larotrectinib is a kinase inhibitor approved for adult and pediatric patients 28 days and older with solid tumors that have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or that have progressed following treatment.

Larotrectinib is tissue agnostic for treatment of solid tumors with this genetic mutation.

Serious adverse reactions that can occur with larotrectinib use include neurotoxicity and hepatotoxicity.

Indications

  • neurotrophic receptor tyrosine kinase-positive solid tumors

For the treatment of neurotrophic receptor tyrosine kinase-positive solid tumors

NOTE: Larotrectinib has been designated an orphan drug by the FDA for the treatment of solid tumors with NTRK-fusion proteins.

Side Effects

  1. abdominal pain
  2. abdominal pain
  3. anemia
  4. anemia
  5. anorexia
  6. anorexia
  7. arthralgia
  8. arthralgia
  9. asthenia
  10. back pain
  11. back pain
  12. cerebral edema
  13. constipation
  14. constipation
  15. cough
  16. dehydration
  17. delirium
  18. diarrhea
  19. diarrhea
  20. dizziness
  21. dizziness
  22. dysarthria
  23. dyspnea
  24. dyspnea
  25. elevated hepatic enzymes
  26. elevated hepatic enzymes
  27. encephalopathy
  28. enterocutaneous fistula
  29. fatigue
  30. fatigue
  31. fever
  32. fever
  33. GI obstruction
  34. GI perforation
  35. headache
  36. hyperamylasemia
  37. hypertension
  38. hypertension
  39. hypoalbuminemia
  40. hypoalbuminemia
  41. hyponatremia
  42. infection
  43. jaundice
  44. leukemia
  45. memory impairment
  46. myalgia
  47. myalgia
  48. nasal congestion
  49. nausea
  50. nausea
  51. neurotoxicity
  52. neurotoxicity
  53. neutropenia
  54. neutropenia
  55. new primary malignancy
  56. paresthesias
  57. pericardial effusion
  58. peripheral edema
  59. pleural effusion
  60. syncope
  61. tremor
  62. vomiting
  63. vomiting
  64. weakness
  65. weight gain
  66. weight gain

Monitoring Parameters

  • LFTs
  • pregnancy testing

Contraindications

  • breast-feeding
  • contraception requirements
  • driving or operating machinery
  • hepatic disease
  • infertility
  • male-mediated teratogenicity
  • pregnancy
  • pregnancy testing
  • reproductive risk